

PTC Therapeutics, Inc. (PTCT)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001070081

PTC Therapeutics, Inc.					
PTCT; healthcare					
Grade		D	 fourth fifth of 371 graded peers percentile 67.0; sampling error 2.5 points; lower is stronger		
Rank		249 of 371			
Profitability		D/E		percentile 78.4	
Solvency		C		percentile 49.6	
Growth and financing		B		percentile 31.9	
Reliability		0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025			
Peer failure rate		0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025			
Size band		over \$2.67B assets total assets \$2.9B			
Standard universe		inside revenue above \$1M and assets above \$10M			
Warnings		none active not computable: fortress balance sheet			
Inputs computable		8 of 14			
Graded from		filings received through Feb 19, 2026 232 days before the rescans; latest periodic filing 10-Q received Jul 30, 2026			
Last close		\$62.55 2026-10-08; market equity \$5.2B			
Price used in grade		None			

D, the sloth
fourth fifth of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it

Nov Jan Mar May Jul Sep

\$62.56

Rescans on file: D from Feb 21, 2026

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 19, 2026

Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are marketing or developing or that would render our products or product candidates obsolete or non-competitive. Our competitors may also obtain marketing authorization for their products more rapidly than we may obtain approval for our products and product candidates, which could result in our competitors establishing a strong market position before we are able to enter the market.


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 78.4						
Gross profitability		not computable	32.2%			latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(1.2%)	(6.6%)	78.4	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 1
Solvency, sleeve percentile 49.6						
Twelve-month failure probability		0.08%	0.07%	51.8	248	2026-06-30
Altman Z double-prime		1.56	(0.31)	30.5	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		2.35x	2.96x	66.6	839	2025-12-31
Growth and financing, sleeve percentile 31.9						
Revenue growth, three-year compound		35.3%	10.0%	19.1	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		57.8%	37.1%	41.7	104	2025-12-31
Asset growth, three years		19.3%	2.1%	21.6	704	2025-12-31
Net share issuance, one year		5.0%	2.5%	45.0	634	2026-02-18

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
244	Dentsply Sirona Inc. (XRAY)	65.7	D	
245	InspireMD, Inc. (NSPR)	65.9	D	dilution, short runway, distress
246	Angiodynamics Inc. (ANGO)	66.2	D	fortress balance sheet
247	AIM ImmunoTech Inc. (AIM)	66.5	D	late filer, degenerate inputs, distress
248	Exagen Inc. (XGN)	66.8	D	dilution, fortress balance sheet
249	PTC Therapeutics, Inc. (PTCT) <	67.0	D	
250	Cardiff Oncology, Inc. (CRDF)	67.3	D	short runway, fortress balance sheet
251	Amylyx Pharmaceuticals, Inc. (AMLX)	67.6	D	short runway, degenerate inputs
252	U S Physical Therapy Inc. (USPH)	67.8	D	
253	American Shared Hospital Services (AMS)	68.1	D	late filer
254	Orchestra BioMed Holdings, Inc. (OBIO)	68.4	D	dilution, short runway, fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	13.3%	8.0%	53
Distance from 52-week high	(30.1%)	(31.4%)	52
EBIT to enterprise value	20.3%	(1.5%)	98
Free cash flow yield	13.5%	(1.0%)	94
Book value to price	(0.03)	0.28	9
Sales to price	0.33	0.31	54
Composite equity issuance, five years	17.1%	20.3%	47
Relative strength against the sector, log excess return	(0.09)	(0.14)	53

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$1.0B
Operating cash flow, four quarters	-\$30.5M

Months of runway	413.0
Days since last periodic filing	71 (10-Q received Jul 30, 2026)
Median daily dollar volume, 63 sessions	\$68.6M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax	\$307.0M	2019-12-31	2020-03-02	10-K	0001070081-20-000064
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$12.1M	2019-12-31	2020-03-02	10-K	0001070081-20-000064
3	assets	us-gaap:Assets	\$1.6B	2019-12-31	2021-02-25	10-K	0001070081-21-000009
4	net income	us-gaap:NetIncomeLoss	\$682.6M	2025-12-31	2026-02-19	10-K	0001104659-26-017575
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$711.2M	2025-12-31	2026-02-19	10-K	0001104659-26-017575
6	assets	us-gaap:Assets	\$2.9B	2025-12-31	2026-02-19	10-K	0001104659-26-017575
7	assets	us-gaap:Assets	\$1.7B	2024-12-31	2026-02-19	10-K	0001104659-26-017575
8	current assets	us-gaap:AssetsCurrent	\$2.3B	2025-12-31	2026-02-19	10-K	0001104659-26-017575
9	current liabilities	us-gaap:LiabilitiesCurrent	\$968.4M	2025-12-31	2026-02-19	10-K	0001104659-26-017575
10	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$3.0B	2025-12-31	2026-02-19	10-K	0001104659-26-017575
11	operating income	us-gaap:OperatingIncomeLoss	\$866.9M	2025-12-31	2026-02-19	10-K	0001104659-26-017575
12	book equity	us-gaap:StockholdersEquity	-\$205.3M	2025-12-31	2026-02-19	10-K	0001104659-26-017575
13	liabilities	us-gaap:Liabilities	\$3.1B	2025-12-31	2026-02-19	10-K	0001104659-26-017575
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.7B	2025-12-31	2026-02-19	10-K	0001104659-26-017575
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$806.8M	2024-12-31	2026-02-19	10-K	0001104659-26-017575
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$937.8M	2023-12-31	2026-02-19	10-K	0001104659-26-017575
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$698.8M	2022-12-31	2025-02-27	10-K	0001070081-25-000012
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$8.9M	2025-12-31	2026-02-19	10-K	0001104659-26-017575
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$107.7M	2024-12-31	2026-02-19	10-K	0001104659-26-017575
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$6.5M	2024-12-31	2026-02-19	10-K	0001104659-26-017575
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$158.4M	2023-12-31	2026-02-19	10-K	0001104659-26-017575
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$28.4M	2023-12-31	2026-02-19	10-K	0001104659-26-017575
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$356.7M	2022-12-31	2025-02-27	10-K	0001070081-25-000012
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$32.0M	2022-12-31	2025-02-27	10-K	0001070081-25-000012
25	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$38.8M	2025-12-31	2026-02-19	10-K	0001104659-26-017575
26	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$696.5M	2025-12-31	2026-02-19	10-K	0001104659-26-017575
27	income tax	us-gaap:IncomeTaxExpenseBenefit	\$14.0M	2025-12-31	2026-02-19	10-K	0001104659-26-017575
28	current assets	us-gaap:AssetsCurrent	\$1.4B	2024-12-31	2026-02-19	10-K	0001104659-26-017575
29	current liabilities	us-gaap:LiabilitiesCurrent	\$581.0M	2024-12-31	2026-02-19	10-K	0001104659-26-017575
30	assets	us-gaap:Assets	\$1.9B	2023-12-31	2025-02-27	10-K	0001070081-25-000012
31	assets	us-gaap:Assets	\$1.7B	2022-12-31	2024-02-29	10-K	0001558370-24-002196
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	82,774,730	2026-02-18	2026-02-19	10-K	0001104659-26-017575
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	78,869,368	2025-02-25	2025-02-27	10-K	0001070081-25-000012